DNMT3A and leukemia: In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, the use of a small molecule (VTP-50469) could indeed reverse myeloid progenitor cell self-renewal prior to leukemia transformation, suggesting that individuals at high risk of developing AML may benefit from preventive targeted epigenetic therapy [86].